About Us

The CardioVere Mission

Our mission is to bring to market a safe, simple and effective peripheral edema measurement enabling CHF patients to conveniently monitor their condition and notify their care team when intervention is required. Providing this measurement and creating a new standard of care will empower patients to take control of their condition to improve health outcomes and reduce hospital readmissions, thus decreasing total cost of care.

CardioVere is a spinout company of ChemImage Corporation
  • Technology platform developer with a 25-year history
  • Leading technology innovation company
  • Invented Molecular Chemical Imaging (MCI)
  • Proven VeroVision® technology platform
  • 191 patents
Find Out More
Proven Defense Technology is the Future of Care
  • ChemImage is dedicated to making the world healthier and safer
  • Data, algorithms, software, machine learning and computer vision are at the heart of our Awareness of Things™ platform, which enables peripheral edema monitoring for CHF patients
  • Our commercialization partner has a strong history of launching products that address market needs

Our Team

CardioVere is being managed as a "lean" organization leveraging experienced resources from ChemImage.

Dr. Chris Post Chief Medical Officer
Amanada McCombs MBA, Chief Financial Officer
Beth Ezar MBA, Chief Marketing Officer
Timothy Myers Business Development Executive
Lew Lanker Product Manager